Oncolytics Biotech Inc. Announces Issuance of Patent for Treatment of Cellular Proliferative Disorders

09-Aug-2007

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,252,817 entitled "viruses for the Treatment of Cellular Proliferative Disorders." The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers).

"This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance